This trial will investigate whether supplementing glycine and N-acetylcysteine can help improve cognitive decline in Alzheimer's disease.
3 Primary · 9 Secondary · Reporting Duration: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Experimental Treatment
Non-Treatment Group
52 Total Participants · 2 Treatment Groups
Primary Treatment: N-acetylcysteine · Has Placebo Group · Phase < 1
Age 55 - 85 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: